Avicanna Inc Total Liabilities
Avicanna Inc total liabilities. Based on the latest financial reports, Avicanna Inc (AVCN) has total liabilities worth CA$10.12 Million CAD (≈ $7.32 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Avicanna Inc (AVCN) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Avicanna Inc (2016–2025)
Total liabilities of Avicanna Inc from 2016 to 2025. This chart illustrates how Avicanna Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Avicanna Inc to see how much of total assets are deployed in long-term investments.
Avicanna Inc Competitors by Total Liabilities
The table below lists competitors of Avicanna Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Takuni Group Public Company Limited
BK:TAKUNI
|
Thailand | ฿2.09 Billion |
|
O.R.T.
TA:ORTC
|
Israel | ILA7.31 Million |
|
Rigsave S.P.A.
XETRA:H68
|
USA | €51.93 Million |
|
Wetouch Technology Inc. Common Stock
NASDAQ:WETH
|
USA | $4.12 Million |
|
Pivotal Metals Ltd
AU:PVT
|
Australia | AU$279.63K |
|
ECOUP OYJ EO 1
F:62H
|
Germany | €12.21 Million |
|
KDA Group Inc
V:KDA
|
Canada | CA$2.06 Million |
|
ICG Enterprise Trust PLC
LSE:ICGT
|
UK | GBX90.60 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Avicanna Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Avicanna Inc.
Liquidity & Leverage Metrics
Avicanna Inc Total Liabilities Ratios Explained
Avicanna Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avicanna Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avicanna Inc (2016–2025)
The table below shows the annual total liabilities of Avicanna Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$9.86 Million ≈ $7.13 Million |
-5.00% |
| 2024-12-31 | CA$10.38 Million ≈ $7.51 Million |
-25.89% |
| 2023-12-31 | CA$14.00 Million ≈ $10.13 Million |
-1.14% |
| 2022-12-31 | CA$14.16 Million ≈ $10.24 Million |
-8.01% |
| 2021-12-31 | CA$15.39 Million ≈ $11.14 Million |
-5.25% |
| 2020-12-31 | CA$16.25 Million ≈ $11.75 Million |
+6.26% |
| 2019-12-31 | CA$15.29 Million ≈ $11.06 Million |
+748.74% |
| 2018-12-31 | CA$1.80 Million ≈ $1.30 Million |
+41.13% |
| 2017-12-31 | CA$1.28 Million ≈ $923.33K |
+939.73% |
| 2016-12-31 | CA$122.76K ≈ $88.80K |
-- |
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios … Read more